Dermpath Diagnostics competitors

Steve Rusckowski is Chairman, President and Chief Executive Officer of Quest Diagnostics. Since joining Quest Diagnostics as President and Chief Executive Officer in May 2012, Mr. Rusckowski has focused on transforming the company, based on its compelling vision of “Empowering better health with diagnostic insights.” Under his leadership, the company has refocused on its core diagnostic information services business, sold non-core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. He was elected Chairman of the Board in December 2016. Prior to joining Quest Diagnostics, Mr. Rusckowski was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies. Mr. Rusckowski is a member of the Board of Directors of Project Hope, a global health education and humanitarian assistance organization. He is also a member of the Board of Directors of the American Clinical Laboratory Association, and served as its Chairman from 2014 to 2017. Mr. Rusckowski earned a Master of Science degree in Management from the Massachusetts Institute of Technology’s Sloan School of Management and a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.

Andrew Walton is a Chief Executive Officer at Miraca Life Sciences and Board Member at OXFORD IMMUNOTEC GLOBAL PLC. He has worked as Senior VP/CIO at LABORATORY CORP OF AMERICA HOLDINGS, Executive In Charge at LABORATORY CORP OF AMERICA HOLDINGS, and Exec VP:Strategic Planning at LABORATORY CORP OF AMERICA HOLDINGS. Andrew attended Yale University and Harvard Business School.

Norma Diaz is a Chief Executive Officer at Community Health Group and is based in Greater San Diego Area.

A co-founder of CBLPath via the CBL acquisition, Carlos Urmacher is certified by the American Board of Pathology in Surgical Pathology and Dermatopathology. He is a member of the U.S. and Canadian Academy of Pathology, a member of the College of American Pathologists, and a fellow of the American Society of Clinical Pathologists. Dr. Urmacher has served as a member of the Board of Trustees and Treasurer of the New York Pathological Society, as a member of the Scientific Advisory Board of the World Health Organization and as a member of the editorial boards of The American Journal of Surgical Pathology and The American Journal of Dermatopathology. Prior to joining CBL in 2000 as Co-Director and Chief of Surgical Pathology, Dr. Urmacher served as Attending Pathologist at North Shore University Hospital – NYU School of Medicine in Manhasset, New York for nine years and as Attending Pathologist at Memorial Sloan-Kettering Cancer Center and Associate Professor of Pathology at Cornell University Medical Center for 13 years. Dr. Urmacher is a frequent lecturer and has authored more than 70 articles and six medical textbook chapters. He graduated with an M.D. degree from the Central University of Venezuela and served as Chief Resident in Pathology at Mount Sinai Hospital, New York and as Chief Fellow in Pathology at Memorial Sloan-Kettering Cancer Center and New York University Hospital. Dr. Urmacher was recently giving the honor of distinguished visitor professor in Pathology by Johns Hopkins.

Kathleen Fondren is a Panelist at Panel of National Pathology Leaders, Chief Operating Officer at CellNetix Pathology and Laboratories, and Chief Executive Officer at CellNetix Pathology and Laboratories and is based in Seattle, Washington. She has worked as Assistant Administrator, Clinical Services at Highline Medical Center. Kathleen attended University of Wyoming between 2008 and 2010.